一分钟看懂
这是一项关于B-cell Malignancy的I 期 / II 期研究，登记的药物或干预包括Tacabrutideg；Sonrotoclax；Zanubrutinib；Mosunetuzumab；Glofitamab；Obinutuzumab，当前状态为招募中。登记地点显示中国福州、广州、苏州、杭州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tacabrutideg；Sonrotoclax；Zanubrutinib；Mosunetuzumab；Glofitamab；Obinutuzumab · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fujian Medical University Union Hospital · 福州
- Sun Yat Sen University Cancer Center · 广州
- The First Affiliated Hospital of Soochow University · 苏州
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan · 杭州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
公开的入选条件
- * Must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF
- * Confirmed diagnosis of a R/R B-cell malignancy
- * Protocol-defined measurable disease
- * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- * Adequate organ function
- * Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for ≥ 7 days after the last dose of sonrotoclax, 30 days after the last dose of ta
- * Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for ≥ 7 days after the last dose of sonrotoclax, 30 days after the last dose of tacabrutideg or z
- * Substudies 1, 3, and 4 Inclusion Criterion:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06634589；登记信息更新于 2026-09-11。